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Abstract 
Human amnion-derived WISH cells synthesize little prostaglandin E 2 at the basal state. However, the cells were stimulated greatly to 
synthesize prostaglandin E 2 by interleukin-1/3 in a dose-dependent manner. Stimulation by interleukin-1/3 was synergistically increased 
by pretreatment of the cells with interferon a or )', which alone were inactive. Synergism by interferons was dose-dependent. Stimulation 
by interleukin-1/3, on the contrary, was inhibited by preincubation of the cells with intedeukin-4. Inhibition by interleukin-4 was also 
dose-dependent. Regulation of prostaglandin E 2 synthesis by cytokines was further examined at the m-RNA level of cyclooxygenase-2. 
Quantitative r verse transcription-polymerase chain reaction indicated that the m-RNA level was not increased by interferon-), but was 
synergistically increased by interferon-)' plus interleukin-1/3. Furthermore, the m-RNA level increased by interleukin-1/3 was attenuated 
by inteleukin-4. These results indicate that regulation of interleukin-1/3-stimulated prostaglandin E 2 synthesis by interferons and 
interleukin-4 is controlled at the m-RNA level of cyclooxygenase-2. 
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1. Introduction 
Interleukin-1 (IL-1) has been shown to stimulate prosta- 
glandin synthesis in cultured mammalian cells including 
human amnion-derived WISH cells [1-3]. IL-1 induced 
synthesis of prostaglandins is thought o involve an induc- 
tion of a novel form of cyclooxygenase, COX-2, in these 
cells [4-6], although a minor induction of a classical 
cyclooxygenase, COX-l, has also been reported [7,8]. 
Other cytokines, growth factors and endotoxins uch as 
tumor necrosis factor-alpha (TNF-a) [4], transforming 
growth factor-beta (TGF-fl) [10], epidermal growth factor 
(EGF) [11] and lipopolysaccharide (LPS) [12] have also 
been reported to induce prostaglandin synthesis in respon- 
sive cells. Interplays of these cytokines and growth factors 
Abbreviations: IL, interleukin; PG, prostaglandin; TNF-a, tumor 
necrosis factor-alpha; LPS, lipopolysaccharide; IFN, interferon; COX, 
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in regulating prostaglandin synthesis have also been de- 
scribed [10,13]. 
Interferons (IFNs), a family of cytokines, are known to 
interfere with viral replication and to induce a variety of 
other physiological responses including growth inhibitory 
and immunoregulatory activities [14]. As prostaglandins 
are potent autocoids thought o be involved in growth and 
immunoregulatory effects [15], it would be interesting to 
examine if IFNs regulate prostaglandin synthesis. 
Interleukin-4 (IL-4) is another cytokine that exhibits a 
broad spectrum of biological activity. It promotes the 
growth and the differentiation of many hematopoietic cells 
in vitro and down-regulates their release of several pro-in- 
flammatory mediators [ 16,17]. As 1L- 1 induces the synthe- 
sis of pro-inflammatory prostaglandins, it is important o 
examine if IL-4 antagonizes the actions of IL-1 by inhibit- 
ing the synthesis of prostaglandins. 
Previously, Kniss et al. [13] reported that IL-1 stimu- 
lated PGE 2 synthesis in WISH cells. This work is an 
extension of the previous findings by examining the effect 
of pretreatment of WISH cells with IFNs and IL-4 on 
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IL-1/3-stimulated PGE 2 synthesis. Our results indicate that 
IFNs amplify IL-1/3-stimulated PGE 2 synthesis and IL-4 
inhibits IL-1/3-enhanced PGE 2 production. Furthermore, 
regulation of IL-1/3-stimulated PGE 2 synthesis by IFNs 
and IL-4 appears to be controlled at the stage of m-RNA 
level of COX-2. 
H202 in 0.025 M citrate buffer, pH 3.5) were added to 
each well and absorbance at650 nm was determined by an 
EIA Reader after 30 min of incubation. Concentration of 
each sample was determined from the standard curve. 
2.4. Quantitation of COX-2 m-RNA levels by reverse tran- 
scription-polymerase chain reaction (RT-PCR) 
2. Materials and methods 
2.1. Materials 
Human amnion cell line (WISH) was obtained from the 
American Type Culture Collection. Interferon (IFN) a and 
Y, interleukin-1/3 (IL-1/3) and interleukin-4 (IL-4) were 
supplied by Gibco-BRL. PGE 2 was purchased from the 
Cayman Chemicals. Rabbit anti-mouse IgG affinity puri- 
fied antibodies were obtained from Pierce Chemicals. 
3,3',5,5'-Tetramethylbenzidine (TMB), bovine serum albu- 
min and Dulbecco's modified Eagle's medium (DMEM) 
were supplied by Sigma Chemicals. Catrimox-14 surfac- 
tant was obtained from Iowa Biotechnology. AMV reverse 
transcriptase and a random primer labelling kit were pur- 
chased from United States Biochemical Corp. dNTPs and 
GeneAmp Taq Polymerase were supplied by Perkin Elmer 
Cetus. 
2.2. Cell culture 
WISH cells were cultured in DMEM supplemented with 
50 t*g/ml gentamicin sulfate and 10% fetal bovine serum. 
The cells were plated at 2 x 10S/well, in triplicate one ml 
per well, and grown for 2 days before treatment. After two 
days of growth, cells were primed with either IFN or IL-4 
for 18 h. Cells were then induced to produce PGE 2 by 
adding IL-1/3 for 4 h before collecting and assaying 
medium for PGE 2 . 
2.3. Enzyme immunoassay (EIA) for PGE 2 
PGE 2 was assayed by a specific EIA with a PGE 2 
monoclonal antibody [1811. Antibody cross-reactions with 
other prostaglandins are: PGA 2 (0.5%), PGB 2 (3.7%), 
PGD 2 (0.15%), PGF2~ (< 0.1%), 6-keto-PGFl~ (< 0.1%) 
and TXB 2 (<0.1%). Briefly, 96-microwell plates were 
first coated with rabbit anti-mouse IgG affinity purified 
antibodies (0.5 /xg per well). The assay was carried out in 
200 tzl of EIA buffer (0.1 M potassium phosphate buffer 
(pH 7.5) containing 0.9% NaC1 and 0.1% bovine serum 
albumin). Diluted PGE 2 antibody (50/zl), PGE 2 standards 
or samples (50 /~1) and diluted PGEz-horseradish peroxi- 
dase conjugate (100 /xl) were added to each well. After 1 
h of incubation at room temperature, each well was washed 
with 200 /xl of washing buffer (0.01 M potassium phos- 
phate buffer (pH 7.5) containing 0.05% Tween 20) three 
times. Substrates (100 /zl of 1.25 mM TMB plus 6 mM 
RNA was extracted from respectively treated WISH 
cells by the Catrimox-14 method [19]. Reverse transcrip- 
tion was carried out in 50 mM Tris-HC1 (pH 8.3), 5 mM 
MgC12, 50 mM KC1, 1 mM DTT, 1 mM dNTP, 1 unit//xl 
RNasin, 2 /zg RNA, 0.5 /zg of COX-2 reverse primer 
5'-CTCGGATCCAAGCT/'CTACAGTTCAGT-3', 0.5 /zg 
of Glyceraldehyde 3-phosphate dehydrogenase (G3PD) re- 
verse primer 5'-TCTAGACGGCAGGTCAGGTCCACC-3' 
and 10 units of AMV reverse transcriptase in a total 
volume of 20 /zl. After incubation at 42°C for 1 h, the 
reverse transcription mixture was heated at 94°C for 3 min 
then put on ice. The mixture was diluted 1:10000 with 
sterile water, and 5 tzl was used for PCR. PCR was carried 
out in a 25-/~1 volume with 10 mM Tris-HCl (pH 8.3), 1.5 
mM MgC12, 50 mM KCI, 0.2 mM dNTP, 0.25 /~g of 
forward and reverse primers, 5 /xg of diluted reverse 
transcription mixture and 1 unit GeneAmp Taq Poly- 
merase. The reaction was run on a Ericomp TwinBlock 
PCR system, with 35 cycles, which were 94°C, 1 rain, 
55°C, 1 min, 72°C, 1.5 min each. The forward and reverse 
primers used for COX-2 and G3PD are 5'-AAGACA- 
GATCATAAGCGAGG-3' ,  5' -ACCCATAAGTCCTT- 
TCAAGGA-3' (COX-2) [5] and 5'-CCACCCATG- 
GCAATTCCATGGCA-3' ,  5 ' -TCTAGACGGCAGGT- 
CAGGTCCACC-3' (G3PD) [20]. After the reaction, 5 /zl 
of PCR mixture was loaded on a 1% agarose gel for gel 
analysis. DNA was transferred to a nylon transfer mem- 
brane with a gel-dryer vacuum without heat for 30 min, 
followed by 4 h of solution prehybridization. COX-2 cDNA 
was labelled by 32p-a-dCTP with a random primer la- 
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Fig. 1. Effect of  IL-1/3, IFNs and IL-4 on PGE 2 synthesis in WISH cells. 
WISH cells were treated by various cytokines and PGE 2 was assayed by 
EIA as described in Section 2. 
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Fig. 2. Effect of increasing concentrations f IFNs on IL-1/3 stimulated 
PGE 2 synthesis. Increasing concentrations f IFNs were used to treat 
WISH cells for 18 h before stimulation f PGE 2 synthesis by IL-1/3 (0.2 
ng/ml) as described inSection 2. 
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Fig. 4. Effect of increasing concentrations f IL-4 on IL-1/3 stimulated 
PGE 2 synthesis. WISH cells were treated with increasing concentrations 
of IL-4 for 18 h before stimulation f PGE 2 synthesis by IL-l/3 (0.2 
ng/ml) as described inSection 2. 
belling kit and 1 X 106 CPM/ml  was used for solution 
hybridization with 50% formamide at 42°C for 16 h. The 
membrane was washed and exposed for autoradiography 
and the autoradiogram was analyzed by a densitometric 
scanner (CAMAG TLC Scanner II). 
2.5. Statist ical analysis 
Each experiment was performed in triplicate. The data 
were expressed as the mean + S.E.M. and are representa- 
tive of 2-3 replications of each experiment. Statistical 
significance was assessed by Student's t-test using a P- 
value of < 0.05. 
3. Results 
IL-1/3 (0.2 ng /ml )  stimulated PGE 2 synthesis in WISH 
cells as shown in Fig. 1. The stimulated synthesis was 
further amplified about three-fold by IFN-c~ (5 ng /ml )  or 
two-fold by IFN-T (5 ng /ml )  added during overnight 
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Fig. 3. Effect of increasing concentrations f IL-1/3 on PGE 2 synthesis in 
IFN-treated and untreated WISH ceils. WISH cells were untreated or
treated with either otlFN or ylFN at 5 ng/ml for 18 h before stimulation 
of PGE 2 synthesis by increasing concentrations f IL-1/3 as described in
Section 2. 
preincubation. However, the IL-lfl-stimulated PGE 2 syn- 
thesis was inhibited by the presence of IL-4 (5 ng /ml )  
during preincubation. Neither IFNs nor IL-4 alone affected 
PGE 2 synthesis in WISH cells. The effect of increasing 
concentrations of IFNs on IL-lfl-stimulated PGE 2 synthe- 
sis is shown in Fig. 2. Amplification of stimulated PGE 2 
synthesis was observed at 0.5 ng /ml  of IFNs. Near maxi- 
mal amplification by IFN-tx was seen at 5 ng/ml ,  whereas 
maximal amplification by INF-T required concentrations 
higher than 5 ng/ml .  The effect of increasing concentra- 
tions of IL- l f l  on stimulation of PGE 2 synthesis in IFN- 
primed WISH cells is shown in Fig. 3. Near-maximal 
stimulation of IFN-primed WISH cells was observed at 1.0 
ng /ml  of IL-1/3. However, non-IFN-primed WISH cells 
require IL-1/3 at concentrations higher than 1.0 ng /ml  to 
achieve maximal stimulation. The effect of increasing 
concentrations of IL-4 on IL-1 fl-stimulated PGE 2 synthe- 
sis is shown in Fig. 4. As low as 0.1 ng /ml  of IL-4 was 
able to inhibit IL-1 fl-stimulated PGE 2 synthesis. A maxi- 
mum inhibition of 70% instead of complete inhibition was 
achieved. The effect of increasing concentrations of IL- 1/3 
on IL-4 induced inhibition of PGE 2 synthesis is shown in 
9. 
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Fig. 5. Effect of increasing concentrations f IL-1/3 on IL-4 induced 
inhibition of PGE 2 synthesis. WISH cells were treated with IL-4 (5 
ng/ml) for 18 h before stimulation of PGE 2 synthesis by increasing 
concentrations f IL-1 fl as described inSection 2. 
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Fig. 6. Quantitative RT-PCR on the m-RNa levels of COX-2 under 
various conditions of cytokine t~reatments. WISH cells were treated with 
IL-1 fl (0.2 ng/ml), ylFN (5 ng/ml) and IL-4 (5 ng/ml) either alone or 
in combination asindicated above under the previously described condi- 
tions. The RNA was extracted and the m-RNA levels of COX-2 were 
quantitated asdescribed in Section 2. 
Fig. 5. IL-4 inhibited IL-IL/3-induced synthesis of PGE 2 at 
all concentrations of IL-1/3 tested. 
To examine if regulation of IL-1/3-stimulated PGE 2 
synthesis by IFNs and IL-4 is controlled at the level of 
m-RNA of COX-2, RNA was extracted from WISH cells 
following various treatments. PCR was carried out with 
internal primers for COX-2 and G3PD respectively. The 
primers used for the specific amplification of COX-2 and 
G3PD predict the generation of 972-bp and 597-bp prod- 
ucts respectively. The primers selected for COX-2 were 
specific for COX-2. The inclusion of G3PD primers was to 
confirm that approximately equal amounts of RNA were 
transcribed. Quantitative RT-PCR indicated that IL-1/3 
increased the amount of m-RNA of COX-2 as shown in 
Fig. 6. The increase was further augmented by IFN-3' 
which alone did not increase the level of mRNA. The level 
of m-RNA induced by IL-1/3 was attenuated by the pre- 
treatment of cells with IL-4 which alone did not affect the 
level of m-RNA. 
4. Discussion 
Interferons have been shown to induce a variety of 
proteins and enzymes [14] and to boost the responses of 
other cytokines [21] and pro-inflammatory agents [22]. We 
have shown that both IFN-a and -3' amplify the IL-1/3-in- 
duced PGE 2 synthesis in WISH cells. IFNs alone were not 
able to induce any PGE:, production. The synergism be- 
tween IFNs and IL-I/3 very much resembles that which 
exists between IFN-T and LPS in nitric oxide system. In 
this system INF-T failed to induce nitric oxide production 
but augmented LPS-induced nitric oxide synthesis dramati- 
cally [22]. The molecular basis of such a synergy was 
attributed to the observation that the combination of IFN- y 
and LPS induced a much higher rate of transcription of the 
nitric oxide synthase gene rather than an increase in m-RNA 
stability. The nature of interaction between IFN-T and 
LPS was further elucidated by the promoter analysis of 
nitric oxide synthase gene [23]. Two cooperative regions 
were found to be responsible for IFN-T and LPS synergis- 
tic responsiveness. We speculate that a similar mechanism 
of regulation of gene expression of COX-2 operates in our 
system. Recently, we cloned and sequenced the promoter 
and adjacent regulatory region of the human COX-2 gene 
[24]. Promoter analysis in response to stimulation by IFNs 
and IL- l f l  is in progress. 
IL-4 appears to inhibit IL-1/3-induced PGE 2 synthesis 
although a maximum of 70% inhibition was achieved at 
high concentrations of IL-4. Previously, Hart et al. [25] 
reported IL-4 suppressed TNF-a, IL-1 and PGE 2 produc- 
tion in human monocytes. Whether inhibition of PGE 2 
synthesis is a direct effect of IL-4 or the consequence of 
decreased synthesis of TNF-a and IL-1 induced by IL-4 is 
not clear, as the latter two agents timulate PGE 2 synthesis 
[3,9]. Our data indicate that IL-4 induced inhibition of 
PGE 2 synthesis is more likely the result of decreased 
production of TNF-a and IL-I. Contrary to our observa- 
tion, Adamson et al. [26] reported very recently that IL-4 
alone stimulated PGE 2 synthesis and also enhanced EGF- 
stimulated PGE 2 production. However, the concentration 
of IL-4 needed to stimulate PGE 2 synthesis was found to 
be exceedingly high (10-100 ng/ml)  in their study. We 
believe that the physiologic function of IL-4 is more 
probably related to antagonizing other growth regulatory 
activities. The mechanism of antagonist action of IL-4 is 
not clear. Recently, Colotta et al. [27] reported that IL-4 
induced the expression and release of IL-1 type II receptor 
in polymorphonuclear cells. They further indicated that 
IL-I acts on myelomonocytic cells through IL-1 type I 
receptor and that IL-1 type II receptor inhibits IL-1 activity 
by acting as a decoy target for IL-1. It is possible that IL-4 
induces IL-1 type II receptor in amnion cells which con- 
tributes to the antagonist action of IL-4. Alternatively, IL-4 
has been shown to induce the expression of 15-1ipoxy- 
genase and the subsequent 15-HETE synthesis [28,29]. The 
15-1ipoxygenase products may inhibit IL- 1/3-induced PGE 2 
synthesis as much as cyclooxygenase-derived products 
stimulate COX-2 gene expression [30]. Whether WISH 
cells are induced by IL-4 to express 15-1ipoxygenase r - 
mains to be determined. 
The effects of IFNs and IL-4 on IL-1 t-stimulated PGE 2 
synthesis appear to correlate well with those on IL-1/3- 
stimulated m-RNA levels of COX-2. These results suggest 
that increased or decreased synthesis of PGE 2 induced by 
cytokines is controlled by the levels of COX-2 m-RNA. 
The fact that IFNs are able to prime WISH cells for 
induction of COX-2 gene expression by other cytokines 
suggests that COX-2 may play a crucial role in mediating 
the antiviral and anticellular effects of IFNs. In this con- 
nection, Chandrabose etal. [31 ] previously reported that an 
IFN-resistant cell line lacks cyclooxygenase activity. 
The significance of our findings is elaborated as fol- 
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lows. It is well  known that prostaglandin production by 
amnion plays an important role in the mechanisms of 
preterm labor and delivery in the setting of  infections. 
These infections appear to cause a local release of cy- 
tokines such as IL-1, TNF-c~ and IFNs from host tissues. 
Both IL-1 and TNF-a  are known to stimulate prosta- 
glandin synthesis from amnion as well as other gestational 
tissues [3,9]. The endogenous release of IFNs may amplify 
the actions of  IL-1 as well  as TNF-c~. Prel iminary results 
indicate that IFN-3~ also amplif ies TNF-ce-induced PGE 2 
synthesis in WISH cells (unpublished data). Therefore, 
IFNs appear to sensitize the cells for a subsequent massive 
release of vasoactive prostaglandins induced by pro-in- 
f lammatory cytokines. On the contrary, IL-4 may be re- 
leased under needed conditions and may serve to antago- 
nize the action of  pro- inf lammatory cytokines released by 
bacterial infections and to prevent women from initiation 
of  unnecessary preterm labor. 
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